Everything you need to win SK Bioscience — in one platform.
Who to reach, what to say, and why now on SK Bioscience — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on SK Bioscience — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
SK bioscience and Sanofi extend partnership to develop next-generation vaccines
Dec 23, 2024•over 1 year ago
Contract Type
partnership
Description
SK bioscience and Sanofi have extended their partnership to co-develop next-generation pneumococcal conjugate vaccines (PCVs) for both pediatric and adult populations. Sanofi will provide an upfront payment of 75.5 billion won ($52 million) to SK bioscience, with additional milestone payments to follow throughout the drug development process. The deal is an expansion of the two companies’ existing collaboration to develop and commercialize a 21-valent PCV candidate GBP410. The global pneumococcal vaccine market is projected to grow to 14.2 trillion won in 2028, up from 11.9 trillion won.
Company Information
Company
SK Bioscience
About
SK Bioscience is a biotechnology company focusing on developing vaccines and biologics. It aims to enhance global health by developing innovative vaccines and biopharmaceuticals. The company is engaged in research, development, and manufacturing of various vaccine products. Recently, it has improved its performance significantly following the acquisition of IDT BioLogica.
Predictive Intelligence
Strategic
ML-powered predictions for SK Bioscience's next move
